[Alternative contrasexual hormone treatment following fibrosing breast irradiation in prostatic carcinoma. Retrospective analysis of 123 patients].
Symptoms and objective parameters of gynecomastia are analysed in 113 patients, who received prophylactic irradiation of the breast (12 Gy in 3 fractions) prior to estrogen therapy of prostatic carcinoma. Another 10 patients were treated equally after estrogens had caused severe complaints. Symptoms increased from 10% to 100% in relation to 4 classes of gynecomastia. They were mild in 27.5%, moderate in 23.9% and severe in 8.8%. A correlation between metric classification and graded symptoms became more evident when only 2 groups were distinguished. With a maximum diameter of 3.5 cm only 17% of the patients had mostly slight discomfort in contrast to 70% of the patients with a gland of more than 3.5 cm in diameter; they revealed moderate or serious complaints. These results indicate that prophylactic radiotherapy may reduce severe complications to less than 10% as compared to 70-80% without irradiation. If gynecomastia has developed, regression by subsequent radiotherapy seems to be impossible; but the intensity of complaints could be reduced in our ten patients. Provided that irradiation precedes estrogen application, this sequence may be considered as a reasonable alternative to expensive antiandrogen therapy.
D001940:Breast / Q000528:radiation effects*; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006177:Gynecomastia / Q000517:prevention & control; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011829:Radiation Dosage
D004958:Estradiol; D004054:Diethylstilbestrol; C008958:polyestradiol phosphate
Die alternative kontrasexuelle Hormontherapie nach Mammafibrosierungsbestrahlung beim Prostatakarzinom. Eine retrospektive Analyse an 123 Patienten.